Clinical Trial Search

Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…

Primary: Treatment Retention — 24; 20; 17; 14 Participants

Primary: Number and Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs) — 21; 94 Participants

Primary: Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks — -2; -2; -1 change in units on a scale — p=0.08

Primary: Percent Probability of Pregnancy Among Users of the SILCS Diaphragm Used With Contraceptive Gel Over 6 Months of Typical Use — 12.5; 9.6 percent probability

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Objective Response at 48 to 72 Hours (FDA Primary Endpoint) — 259; 266; 72; 63 Participants

Primary: Kaplan-Meier Estimates for Time to Meaningful Pain Relief — 42.917; NA minutes

Primary: Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral…

Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants

Primary: Geometric Mean Titers (GMTs) to HPV Types 16 and 18 — 6739.5; 6887.4; 1956.6; 1795.6 milli Merck Units/mL — p=<0.001

Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale

Primary: Percentage of Participants Achieving Seroprotection Using a Serum Bactericidal Assay Human Complement With Antibody Titers ≥ 1:8 for Meningococcal Serogroups A, C, Y…

Primary: Number of Participants With Solicited Adverse Reactions — 507; 480 Count of Participants

Primary: Phase II: Treatment Compliance (Number of Compliant Patients) — 12; 44 Participants